文献速递系统性红斑狼疮

用于临床试验的新型循证狼疮多变量结局评分的开发与验证

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
PubMed 文献 · Arthritis Rheumatol · 2018-08-03

研究基于BLISS-76和BLISS-52两项贝利尤单抗随机对照试验数据,开发并验证了狼疮多变量结局评分(LuMOS)。LuMOS纳入SELENA-SLEDAI评分降低≥4分、C4升高、抗dsDNA滴度下降及BILAG器官系统变化等指标。在两项试验所有分析中,贝利尤单抗1 mg或10 mg组平均LuMOS评分均显著高于安慰剂组(P<0.0001),且LuMOS效应量显著高于SRI-4。

要点

  • LuMOS评分纳入SELENA-SLEDAI降低≥4分、C4升高、抗dsDNA下降及BILAG肾脏无恶化伴黏膜皮肤改善等指标。
  • BLISS-76和BLISS-52所有分析中,贝利尤单抗1 mg或10 mg组平均LuMOS评分均显著高于安慰剂组(P<0.0001)。
  • LuMOS效应量显著高于SRI-4,且能揭示SRI-4未显示的贝利尤单抗1 mg组与安慰剂组差异。

核心结论

  • 基于BLISS-76数据开发并以BLISS-52数据验证的循证LuMOS评分系统,较SRI-4具有更优的应答者与非应答者区分能力。
  • 作者认为使用LuMOS可能提高未来狼疮试验分析的效率与检验效能。

研究设计与样本

  • LuMOS公式通过分析贝利尤单抗获批依据的两项关键试验——52周BLISS-52和76周BLISS-76的原始数据开发。
  • 以BLISS-76试验数据为学习集,采用多变量逻辑回归分析优化对10 mg/kg贝利尤单抗组与安慰剂组随访前52周结局的区分。
  • 使用BLISS-52试验的独立验证数据集评估LuMOS性能。

主要发现

  • LuMOS模型纳入以下应答标准:SELENA-SLEDAI评分降低≥4分、C4水平升高、抗dsDNA滴度下降、BILAG器官系统表现变化(肾脏成分无恶化、黏膜皮肤成分改善)。
  • 泼尼松剂量降低和C3水平升高对LuMOS总评分影响很小。
  • 在BLISS-76和BLISS-52试验数据集的所有分析中,贝利尤单抗1 mg或10 mg组平均LuMOS评分均显著高于安慰剂组(P<0.0001)。
  • 与SRI-4表现相反,LuMOS揭示了活性治疗组(BLISS-76队列中1 mg贝利尤单抗)与安慰剂组之间的显著差异。
  • LuMOS的效应量显著高于SRI-4。

关键数值与推荐

  • LuMOS评分包含的应答标准为:SELENA-SLEDAI评分降低≥4分、C4水平升高、抗dsDNA滴度下降、BILAG肾脏成分无恶化且黏膜皮肤成分改善。
  • 在BLISS-76和BLISS-52数据集所有分析中,贝利尤单抗1 mg或10 mg组平均LuMOS评分均显著高于安慰剂组(P<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Trials of new systemic lupus erythematosus (SLE) treatments are hampered by the lack of effective outcome measures. To address this, we developed a novel Lupus Multivariable Outcome Score (LuMOS) and assessed its performance using data from 2 randomized controlled trials of belimumab in patients with SLE. METHODS: The LuMOS formula was developed by analyzing raw data from 2 pivotal trials, the Study of Belimumab in Subjects with SLE 52-week (BLISS-52) and 76-week (BLISS-76) trials, which are the basis for approval of belimumab. Using the BLISS-76 trial data as the learning data set, we carried out multivariable logistic regression analyses to optimize discrimination of outcomes between patients treated with 10 mg/kg belimumab and patients receiving placebo over the first 52 weeks of follow-up. In addition, the performance of LuMOS was assessed using an independent validation data set from the BLISS-52 trial. RESULTS: The LuMOS model incorporated the following response criteria: a ≥4-point reduction on the Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index, an increase in C4 levels, a decrease in anti-double-stranded DNA titers, and changes in the British Isles Lupus Assessment Group scores for organ system manifestations (no worsening in renal components, and improvements in mucocutaneous components). A decrease in the prednisone dose and increase in C3 levels had very minor impacts on the total LuMOS score. In all analyses of the BLISS-76 and BLISS-52 trial data sets, the mean LuMOS scores were significantly higher (P < 0.0001) in patients treated with 1 mg or 10 mg belimumab compared to placebo. In contrast to the performance of the SLE Responder Index 4 (SRI-4), the LuMOS revealed significant differences between the active treatment group (1 mg belimumab in the BLISS-76 cohort) and placebo group. The effect sizes were significantly much higher with the LuMOS than with the SRI-4. CONCLUSION: The evidenced-based LuMOS outcome scoring system, developed with data from the BLISS-76 trial of belimumab in patients with SLE and validated with data from the BLISS-52 trial, exhibits a superior capacity to discriminate responders from nonresponders when compared to the SRI-4. Use of the LuMOS may improve the efficiency and power of analyses in future lupus trials.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, et al. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials. Arthritis Rheumatol. 2018. PMID: 29648686. doi:10.1002/art.40522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。